RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)

Sponsor
Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular (Other)
Overall Status
Unknown status
CT.gov ID
NCT01239953
Collaborator
Hospital San Carlos, Madrid (Other), B.Braun Surgical SA (Industry), Abbott Medical Devices (Industry)
190
25
2
7.6

Study Details

Study Description

Brief Summary

Treatment of patients with bare metal stent restenosis remains a challenge. This study will assess which interventional strategy (paclitaxel-eluting balloon vs everolimus-eluting stent) is superior in the treatment of patients suffering from bare metal stent restenosis.

Condition or Disease Intervention/Treatment Phase
  • Device: Coronary angioplasty using the paclitaxel-eluting balloon
  • Device: Coronary angioplasty using the everolimus-eluting stent
Phase 4

Detailed Description

Treatment of patients with bare metal stent restenosis remains a major clinical and technical challenge. Currently, drug-eluting stents are widely used in the management of these patients. Recently, the value of the paclitaxel-eluting balloon in this clinical setting has been suggested. However, there is only scarce observational data on the value of this new balloon in patients with bare metal stent restenosis.

This prospective, multicenter, randomized clinical trial will compare two different interventional strategies (namely, paclitaxel-eluting balloon vs everolimus-eluting stent) in the treatment of patients with bare metal stent restenosis.

Study Design

Study Type:
Interventional
Actual Enrollment :
190 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent). A Prospective, Multicenter and Randomized Clinical Trial
Study Start Date :
Jan 1, 2010
Anticipated Primary Completion Date :
Jul 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Paclitaxel-eluting balloon

Paclitaxel-eluting balloon (SeQuent Please, B. Braun)

Device: Coronary angioplasty using the paclitaxel-eluting balloon
Balloon angioplasty

Active Comparator: Everolimus-eluting stent

Everolimus-eluting stent (Xience Prime, Abbott Vascular)

Device: Coronary angioplasty using the everolimus-eluting stent
Stent implantation

Outcome Measures

Primary Outcome Measures

  1. Minimal lumen diameter [Late angiographic follow-up (6-9 months)]

    Comparison of minimal lumen diameter at late angiographic follow-up (6-9 months) between the 2 treatment strategies (by quantitative coronary angiography)

Secondary Outcome Measures

  1. Combined clinical and angiographic end-points [6-9 months, 1 year and 3 years]

    A) Efficacy outcomes: A1) Angiographic: 1) Restenosis rate, 2) % diameter stenosis, 3) acute gain, 4) late loss, 5) net gain A2) Composite of death, myocardial infarction, target vessel revascularization and analysis of individual events B) Safety Outcomes: Stent thrombosis, Bleeding episodes. C) Pre-specified variables for subgroup analysis (RIBS I) D) Stratification (length and edge). Type of stent E) Influence of clinical variables and restenosis patterns on outcome

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 85 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
PATIENT:
  • Age between 20 and 85 years

  • Signed informed consent

  • Acceptance of late angiographic control (6-9 months)

  • Angina and / or objective evidence of ischemia

LESION:
  • In-Stent restenosis (> 50% visual) any bare metal stent

  • Knowledge of prior stent location

Exclusion Criteria:
PATIENT:
  • Inclusion in another clinical research protocol

  • Women of childbearing age

  • Severe associated systemic disease (including renal or liver failure)

  • Severe depression of left ventricular ejection fraction (LVEF <25%)

  • Disease that affects life expectancy

  • Recent myocardial infarction ( <7 days)

  • Time of implantation of the previous BMS <1 month

  • Severe difficulties expected for late angiographic study

LESION:
  • Angiographic failure during implementation of initial stent(residual stenosis> 50%)

  • Image of large thrombus in-stent (> vessel diameter)

  • Tortuosity or Ca + + with very severe difficulties during prior stent deployment

  • Vessel diameter <2 mm (visual estimate)

  • Restenosis only "outside" the stent (The edge of the stent is not affected)

  • Completely occlusive restenosis (100%, TIMI 0)

  • Very diffuse restenosis (> 30 mm length)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital Central de Asturias Oviedo Asturias Spain 33006
2 Hospital Universitari de Bellvitge L'Hospitalet de Llobregat Barcelona Spain 08907
3 Hospital Universitario Marques de Valdecilla Santander Cantabria Spain 39008
4 Hospital Universitari Son Dureta Palma de Mallorca Illes Balears Spain 07014
5 Hospital Universitario Puerta de Hierro Majadahonda Majadahonda Madrid Spain 28222
6 Hospital Provincial de Navarra Pamplona Navarra Spain 31008
7 Complejo Hospitalario Universitario de Vigo Vigo Pontevedra Spain 36204
8 Complejo Hospitalario Universitario A Coruña A Coruña Spain 15006
9 Hospital General Universitario de Alicante Alicante Spain 03010
10 Complejo Hospitalario de Torrecardenas Almeria Spain 04009
11 Hospital Universitario Infanta Cristina Badajoz Spain 06080
12 Hospital de la Santa Creu i Sant Pau Barcelona Spain 08025
13 Hospital Universitari Vall d'Hebron Barcelona Spain 08035
14 Hospital Clinic de Barcelona Barcelona Spain 08036
15 Hospital Universitario Virgen de las Nieves Granada Spain 18014
16 Hospital Universitario de La Princesa Madrid Spain 28006
17 Hospital Clinico San Carlos Madrid Spain 28040
18 Hospital Universitario 12 de Octubre Madrid Spain 28041
19 Hospital Universitario La Paz Madrid Spain 28046
20 Hospital Universitario Carlos Haya Malaga Spain 29010
21 Hospital Universitario Virgen de la Victoria Malaga Spain 29010
22 Complejo Hospitalario de Toledo Toledo Spain 45004
23 Hospital Clinico Universitario de Valencia Valencia Spain 46010
24 Hospital General Universitario de Valencia Valencia Spain 46014
25 Hospital Universitario Miguel Servet Zaragoza Spain 50009

Sponsors and Collaborators

  • Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular
  • Hospital San Carlos, Madrid
  • B.Braun Surgical SA
  • Abbott Medical Devices

Investigators

  • Study Director: Fernando Alfonso, MD, PhD, Hospital San Carlos, Madrid

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Fernando Alfonso, MD, PhD, Hospital Universitario Clínico San Carlos, Madrid. Cardiovascular Institute. Cardiac Department. Interventional Cardiology Unit, Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular
ClinicalTrials.gov Identifier:
NCT01239953
Other Study ID Numbers:
  • RIBS V
First Posted:
Nov 15, 2010
Last Update Posted:
Feb 27, 2012
Last Verified:
Feb 1, 2012
Keywords provided by Fernando Alfonso, MD, PhD, Hospital Universitario Clínico San Carlos, Madrid. Cardiovascular Institute. Cardiac Department. Interventional Cardiology Unit, Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 27, 2012